secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001213900-24-019557
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q4 net loss $42.1M; cash $329.4M; $15M royalty amendment & $30M placement
--------------------------------------------------------------------------------

- Q4 revenue $23.9M (up from $22.0M); Q4 net loss $42.1M ($0.22/sh) vs $59.7M ($0.32).
- Cash and investments $329.4M at Dec 31, 2023, down from $505.0M; runway into Q3 2026.
- Received $15M from Healthcare Royalty to cancel reversionary interest in royalties.
- Completed $30M private placement with TCG Crossover Fund in March 2024.
- Phase 2b study of rezpegaldesleukin for atopic dermatitis initiated; data expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024019557/0001213900-24-019557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024019557/ea0201095-8k_nektarther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-019557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer